374 related articles for article (PubMed ID: 23372164)
1. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
2. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
Elena C; Gallì A; Such E; Meggendorfer M; Germing U; Rizzo E; Cervera J; Molteni E; Fasan A; Schuler E; Ambaglio I; Lopez-Pavia M; Zibellini S; Kuendgen A; Travaglino E; Sancho-Tello R; Catricalà S; Vicente AI; Haferlach T; Haferlach C; Sanz GF; Malcovati L; Cazzola M
Blood; 2016 Sep; 128(10):1408-17. PubMed ID: 27385790
[TBL] [Abstract][Full Text] [Related]
3. Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L; Garcia O; Arnan M; Xicoy B; Fuster F; Cabezón M; Coll R; Ademà V; Grau J; Jiménez MJ; Pomares H; Marcé S; Mallo M; Millá F; Alonso E; Sureda A; Gallardo D; Feliu E; Ribera JM; Solé F; Zamora L
Oncotarget; 2016 Aug; 7(35):57021-57035. PubMed ID: 27486981
[TBL] [Abstract][Full Text] [Related]
4. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Br J Haematol; 2021 Feb; 192(3):474-483. PubMed ID: 32501529
[TBL] [Abstract][Full Text] [Related]
5. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment in chronic myelomonocytic leukemia (CMML).
Germing U; Kündgen A; Gattermann N
Leuk Lymphoma; 2004 Jul; 45(7):1311-8. PubMed ID: 15359628
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
[TBL] [Abstract][Full Text] [Related]
8. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD
Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307
[TBL] [Abstract][Full Text] [Related]
9. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
Am J Hematol; 2018 Jan; 93(1):65-73. PubMed ID: 29023992
[TBL] [Abstract][Full Text] [Related]
10. Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
González JS; Perusini MA; Basquiera AL; Alfonso G; Fantl D; Lima WM; Nucifora E; Lazzarino C; Novoa V; de Andrade Silva MC; Larripa IB; Rocha V; Arbelbide J; Velloso EDRP; Belli CB
Ann Hematol; 2021 Jun; 100(6):1439-1449. PubMed ID: 33932168
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.
Onida F; Kantarjian HM; Smith TL; Ball G; Keating MJ; Estey EH; Glassman AB; Albitar M; Kwari MI; Beran M
Blood; 2002 Feb; 99(3):840-9. PubMed ID: 11806985
[TBL] [Abstract][Full Text] [Related]
12. [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].
Germing U; Strupp C; Meckenstock G; Giagounidis A; Minning H; Aul C
Med Klin (Munich); 1999 Sep; 94(9):467-72. PubMed ID: 10544608
[TBL] [Abstract][Full Text] [Related]
13. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B; Germing U; Jimenez MJ; Garcia O; Garcia R; Schemenau J; Pedro C; Luño E; Bernal T; González B; Strupp C; Ardanaz M; Kuendgen A; Cedena MT; Neukirchen J; Calabuig M; Brunet S; Medina A; Amigo ML; Ramos F; Callejas M; Díez-Campelo M; Bailén A; Collado R; Vicente A; Arnan M; Valcarcel D; Arilla MJ; Zamora L; Benlloch L; Sanz G
Eur J Haematol; 2016 Jul; 97(1):33-8. PubMed ID: 26341961
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.
Calvo X; Nomdedeu M; Santacruz R; Martínez N; Costa D; Pereira A; Estrada N; Xicoy B; Esteve J; Nomdedeu B
Leuk Res; 2015 Jul; ():. PubMed ID: 26354683
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
16. Improving the accuracy of prognostication in chronic myelomonocytic leukemia.
Kaivers J; Schuler E; Hildebrandt B; Betz B; Rautenberg C; Haas R; Kobbe G; Gattermann N; Germing U
Expert Rev Anticancer Ther; 2020 Aug; 20(8):703-714. PubMed ID: 32700646
[TBL] [Abstract][Full Text] [Related]
17. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
19. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
Motohashi K; Fujisawa S; Doki N; Kobayashi T; Mori T; Usuki K; Tanaka M; Fujiwara S; Kako S; Aoyama Y; Onoda M; Yano S; Gotoh M; Kanamori H; Takahashi S; Okamoto S;
Leuk Lymphoma; 2018 Jun; 59(6):1332-1337. PubMed ID: 29032731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
